Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Expanding their relationship, PharmaEssentia gets more compounds from Kinex

Executive Summary

Two years after they first met up, Kinex Pharmaceuticals Inc. (cancer and immune therapies) granted Taiwanese biotech PharmaEssentia Corp. licenses to more compounds from its pipeline, this time handing over exclusive development and commercialization rights in Singapore and Taiwan to the cancer projects Oraxol (paclitaxel) and Oratecan (irinotecan).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal

Related Companies